DevelopmentsProduct News

Dasatinib Clonmel

Clonmel Healthcare is delighted to announce the launch of Dasatinib Clonmel 20mg, 50mg, 70mg and 100mg Film-coated Tablets.

Dasatinib Clonmel is indicated for the treatment of adult patients with Ph+ acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy.

Full prescribing information is available on request or alternatively please go to  Medicinal product subject to medical prescription.

Please contact Clonmel Healthcare on 01-6204000 if you require any additional information.

PA 0126/310/001-004. PA Holder: Clonmel Healthcare Ltd., Clonmel, Co. Tipperary. Date prepared: April 2020. 2020/ADV/DAS/036H

Show More

Related Articles


Please Confirm

This website is only for the eyes of medical professionals. Are you a medical professional?